Michael Wheatcroft
Direttore Tecnico/Scientifico/R&S presso TELIX PHARMACEUTICALS LIMITED
Posizioni attive di Michael Wheatcroft
| Società | Posizione | Inizio | Fine |
|---|---|---|---|
| TELIX PHARMACEUTICALS LIMITED | Direttore Tecnico/Scientifico/R&S | - | - |
Storia della carriera di Michael Wheatcroft
Precedenti posizioni note di Michael Wheatcroft
| Società | Posizione | Inizio | Fine |
|---|---|---|---|
Medimmune UK Ltd.
 Medimmune UK Ltd. Chemicals: Major DiversifiedProcess Industries Medimmune UK Ltd. manufactures chemical products. The company was founded on October 6, 1999 and is headquartered in Speke, the United Kingdom. | Corporate Officer/Principal | - | - |
Avipep Pty Ltd.
 Avipep Pty Ltd. Medical SpecialtiesHealth Technology Avipep Pty Ltd. commercializes protein biopharmaceuticals and in-vivo diagnostic products. It focuses on developing Avibodies as a platform for targeting cells in the body with a focus on antibody-drug conjugates (ADC) for the treatment of cancer. The company was founded on April 7, 2005 and is headquartered in Parkville, Australia. | Corporate Officer/Principal | - | - |
Formazione di Michael Wheatcroft
| University of Cambridge | Doctorate Degree |
Statistiche
Distribuzione geografica
| Regno Unito | 3 |
| Australia | 3 |
Posizioni
| Corporate Officer/Principal | 2 |
| Chief Tech/Sci/R&D Officer | 1 |
| Doctorate Degree | 1 |
Settori
| Health Technology | 3 |
| Consumer Services | 2 |
| Process Industries | 2 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
| Società quotate in Borsa | 1 |
|---|---|
| TELIX PHARMACEUTICALS LIMITED | Health Technology |
| Aziende private | 2 |
|---|---|
Medimmune UK Ltd.
Medimmune UK Ltd. Chemicals: Major DiversifiedProcess Industries Medimmune UK Ltd. manufactures chemical products. The company was founded on October 6, 1999 and is headquartered in Speke, the United Kingdom. | Process Industries |
Avipep Pty Ltd.
Avipep Pty Ltd. Medical SpecialtiesHealth Technology Avipep Pty Ltd. commercializes protein biopharmaceuticals and in-vivo diagnostic products. It focuses on developing Avibodies as a platform for targeting cells in the body with a focus on antibody-drug conjugates (ADC) for the treatment of cancer. The company was founded on April 7, 2005 and is headquartered in Parkville, Australia. | Health Technology |
- Borsa valori
- Insiders
- Michael Wheatcroft
- Esperienza
